Logo Logo
Switch Language to German
Jensen, Christoph J.; Richardt, Gcrt; Tolg, Ralph; Erglis, Andrcjs; Skurk, Carsten; Jung, Werner; Neumann, Franz-Josef; Stangl, Karl; Brachmann, Johannes; Fischer, Dieter; Mehilli, Julinda; Rieber, Johannes; Wiemer, Marcus; Schofer, Joachim; Sack, Stefan; Naber, Christoph K. (2018): Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. In: Eurointervention, Vol. 14, No. 10: pp. 1096-1103
Full text not available from 'Open Access LMU'.


Aims: Aitken several studies have shown positive outcomes after the use of drug-coated balloons (DCB) for in-stmt restenosis (ISR), data on randomised controlled trials versus latest-generation drug-eluting stents (DES) are limited. Therefore, in this randomised trial, we sought to evaluate whether a butyryltri-hexyl citrate (BTHC)-based paclitaxel DCB is non-inferior to a biodegradable polymer sirolimus-eluting stem (BP-SFS) therapy in patients with ISR in either a bare metal stent (BMS) or DES. Methods and results: A total of 229 patients with ISR in BMS or DES from 13 German centres and one Latvian centre were 2:1 randomly allocated to DCB (n=157) or DES (n=72). The primary efficacy endpoint was defined as in-stent late lumen loss (LLL) at six months, and the primary safety endpoint was target lesion failure (TLF) at 12 months. LLL in the DCB arm was 0.03 +/- 0.40 mm compared to 0.20 +/- 0.70 mm in the DES arm (p=0.40). DCB proved to be non-inferior to DES (Delta=-0.17 +/- 0.52 mm, 97.5% CI -infinity;-0.01];p<0.0001). At 12 months, Kaplan-Meier TLF estimates were 16.7% in the DCB arm and 14.2% in the DES arm (p=0.65) and remained similar at 18 months (DCB versus DES: 17.4% versus 19.5%, p=0.88). Conclusions: In patients with DES or BMS ISR, treatment with a paclitaxel DCB showed similar LLL at six months and TLF rates up to 18 months compared to a second-generation sirolimus DES.